COVID-19 in a young liver transplant recipient: caution for drug-drug interactions

J Gastrointestin Liver Dis. 2020 Sep 9;29(3):470. doi: 10.15403/jgld-2672.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acute Kidney Injury* / chemically induced
  • Acute Kidney Injury* / diagnosis
  • Acute Kidney Injury* / prevention & control
  • Adult
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects
  • Betacoronavirus / isolation & purification
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques / methods
  • Coronavirus Infections* / diagnosis
  • Coronavirus Infections* / drug therapy
  • Coronavirus Infections* / physiopathology
  • Darunavir* / administration & dosage
  • Darunavir* / adverse effects
  • Drug Interactions*
  • Drug Monitoring / methods
  • Humans
  • Hydroxychloroquine* / administration & dosage
  • Hydroxychloroquine* / adverse effects
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / blood
  • Liver Transplantation / methods*
  • Male
  • Pandemics*
  • Pneumonia, Viral* / diagnosis
  • Pneumonia, Viral* / drug therapy
  • Pneumonia, Viral* / physiopathology
  • Prednisone* / administration & dosage
  • Prednisone* / adverse effects
  • Risk Adjustment / methods
  • Ritonavir* / administration & dosage
  • Ritonavir* / adverse effects
  • SARS-CoV-2
  • Tacrolimus* / administration & dosage
  • Tacrolimus* / adverse effects
  • Tacrolimus* / blood
  • Transplant Recipients
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Immunosuppressive Agents
  • Hydroxychloroquine
  • Ritonavir
  • Prednisone
  • Tacrolimus
  • Darunavir